Treatment of cytomegalovirus disease in solid organ transplant recipients: Markers of inflammation as predictors of outcome

Transplantation

Volumn 94, Issue 10, 2012, Pages 1060-1065

  Rollag, Halvor ^a,d   Åsberg, Anders ^b   Ueland, Thor ^a   Hartmann, Anders ^c,d   Jardine, Alan G ^e   Humar, Atul ^f   Pescovitz, Mark D ^g   Bignamini, Angelo A ^h   Aukrust, Pål ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytomegalovirus; Inflammation; Outcome; Transplantation; Treatment

Indexed keywords

CXCL16 CHEMOKINE; GANCICLOVIR; PENTRAXIN 3; VALGANCICLOVIR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD LEVEL; CELL ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; INFLAMMATION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VON WILLEBRAND FACTOR BLOOD LEVEL;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINES, CXC; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RECEPTORS, SCAVENGER; SERUM AMYLOID P-COMPONENT; TRANSPLANTATION; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84870251979     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826c39de     Document Type: Article

References (30)

1. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166.
2. Valderhaug TG, Hjelmesaeth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007; 84: 1125.
3. Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005; 11: 518.
4. Dengler TJ, Raftery MJ, Werle M, et al. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1beta. Transplantation 2000; 69: 1160.
5. Scholz M, Cinatl J, Gross V, et al. Impact of oxidative stress on human cytomegalovirus replication and on cytokine-mediated stimulation of endothelial cells. Transplantation 1996; 61: 1763.
6. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675.
7. Lisboa LF, Kumar D, Wilson LE, et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93: 195.
8. Nordoy I, Muller F, Nordal KP, et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000; 181: 51.
9. Nordoy I, Muller F, Nordal KP, et al. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 2000; 120: 333.
10. Bolovan-FrittsCA, Spector SA. Endothelial damage from cytomegalovirusspecific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2008; 111: 175.
11. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
12. Tong CY, Bakran A, Williams H, et al. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol 2001; 64: 29.
13. Krishnan A, Zhou W, Lacey SF, et al. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transplant Infect Dis 2010; 12: 363.
14. Helantera I, Egli A, Koskinen P, et al. Viral impact on long-term kidney graft function. Infect Dis Clin N Am 2010; 24: 339.
15. Abel S, Hundhausen C, Mentlein R, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172: 6362.
16. Fukumoto N, Shimaoka T, Fujimura H, et al. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 2004; 173: 1620.
17. Heydtmann M, Lalor PF, Eksteen JA, et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174: 1055.
18. Hofnagel O, Engel T, Severs NJ, et al. SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion. Atherosclerosis 2011; 217: 371.
19. Xu Y, Ganem D. Induction of chemokine production by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Gen Virol 2007; 88: 46.
20. Raki-Sasaki K, Tanaka T, Ebisuno Y, et al. Dynamic expression of chemokines and the infiltration of inflammatory cells in the HSVinfected cornea and its associated tissues. Ocul Immunol Inflamm 2006; 14: 257.
21. Limou S, Coulonges C, Herbeck JT, et al. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis 2010; 202: 908.
22. Landro L, Damas JK, Halvorsen B, et al. CXCL16 in HIV infection-a link between inflammation and viral replication. Eur J Clin Invest 2009; 39: 1017.
23. Deban L, Jaillon S, Garlanda C, et al. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 2011; 343: 237.
24. Bozza S, Bistoni F, Gaziano R, et al. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 2006; 108: 3387.
25. Kahl M, Siegel-Axel D, Stenglein S, et al. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol 2000; 74: 7628.
26. The TH, Kas-Deelen AM, de Maar EF, et al. Cellular and humoral parameters for vascular damage in blood during cytomegalovirus infections. Transplant Proc 2001; 33: 1813.
27. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205.
28. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
29. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
30. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebocontrolled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006; 154: 537.